Choice of cancer test can boost patient compliance
By Stephen Robinson, 12 April 2012
Failing to offer a choice of faecal occult blood (FOB) testing alongside colonoscopy may deter patients from completing bowel cancer screening, research suggests.
A study from the University of Washington School of Medicine found patients offered colonoscopy alone were 45% less likely to adhere to screening.
The research suggests more patients may adhere to the NHS bowel cancer screening programme if they were offered a choice of tests. The authors said patient preferences must be taken into account when offering screening.
The NHS Bowel Cancer Screening Programme sends a FOB test to all men and women aged 60-69 every two years.
The DH launched its £8.5m Be Clear On Cancer awareness campaign earlier this year. It is part of a push to boost early detection.
The NHS was told to expect to deliver an extra 15,000 colonoscopies in England during the campaign. Experts have said the NHS may struggle to cope with rising demand.
Researchers said evidence suggests adherence to screening is more important than the specific test used.
In the study, researchers enrolled 997 participants aged 50-79, of whom 58% completed screening.
Just 38% of those offered colonoscopy attended screening. This compared with 67% of those recommended to have FOB testing.
Compliance was highest among those offered a choice between the two, at 69%, though this was not statistically different from the FOB group.
Researchers also found differences in adherence to colorectal cancer screening tests between ethnic groups.
They said reducing barriers to access, such as offering a choice of test, could improve uptake. It follows research from the University of Oxford last year, which found that patients sent a letter from their GP advising they complete a bowel cancer test kit were more likely to do so.
- Expect more consultations in cancer campaign, GPs told
- Minister denies cancer test pressure
- Exclusive: Scan crisis threat to cancer diagnosis
- GPs use inflatable colon to spread cancer message
- National bowel cancer ads backed by £8.5m
- GP letter boosts bowel cancer screening uptake, study finds
- Clinical Review: Colorectal cancer
- Related MIMS Guidelines and Summaries
- Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy for Treating Metastatic Colorectal Cancer that has Progressed Following Prior Oxaliplatin-Based Chemotherapy (TA307)
- Pixantrone Monotherapy for Treating Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B-cell Lymphoma (TA306)
- Bosutinib for Previously Treated Chronic Myeloid Leukaemia (TA299)
Latest Articles from GP
Latest jobs Jobs web feed
- Salaried GP Gloucester House Medical Centre Competitive Salary , Urmston, Trafford
- Full or part-time Salaried GP Opportunity, Hampshire Coast Merco Excellent salary + GMC paid, Hampshire, South East region
- GP Jobs Calgary and Edmonton, Alberta, Canada EU Health Staff Ltd Between $280,000 and $325,000 or more , North America
- Consultant or GPSI in Dermatology required in WORCESTER, Up to £500 per session + Benefits Career Doctors Up to £500 per session + NHS Pension + 6 weeks leave + paid study leave, Worcester, Worcestershire
- Consultant or GPSI in Dermatology required in Oldham, Up to £500 per session + Benefits Career Doctors Up to £500 per session + NHS Pension + 6 weeks leave + paid study leave, Greater Manchester
- Salaried GP North London - Enfield Eagle House Surgery Salary Negotiable, London (North), London (Greater)